AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate
AbCellera Biologics Q1 2024 GAAP EPS $(0.14) Beats $(0.16) Estimate, Sales $9.954M Miss $10.836M Estimate
abCellera Biologics 2024年第一季度GAAP每股收益美元（0.14美元）超过预期（0.16美元），销售额为995.4万美元，未达到1083.6万美元的预期
AbCellera Biologics (NASDAQ:ABCL) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.16) by 12.5 percent. The company reported quarterly sales of $9.954 million which missed the analyst consensus estimate of $10.836 million by 8.14 percent. This is a 18.36 percent decrease over sales of $12.192 million the same period last year.
ABCellera Biologics（纳斯达克股票代码：ABCL）公布的季度亏损为每股0.14美元，比分析师共识估计的美元（0.16美元）高出12.5％。该公司公布的季度销售额为995.4万美元，比分析师共识估计的1083.6万美元低8.14％。这比去年同期的1219.2万美元的销售额下降了18.36％。